Modular Medical Appoints Insulin Pump Veteran, Eyes Aggressive Global Rollout for Pivot Device – ( $MODD $PODD )

By John F. Heerdink, Jr.

Modular Medical (NASDAQ: MODD) is entering a transformational phase with the appointment of David Bosshard as Head of International Operations, marking the company’s most ambitious push toward global expansion and market leadership in diabetes care technology. Bosshard’s proven expertise in scaling European launches for Insulet’s (PODD) Omnipod & Ypsomed’s YpsoPump, potentially positions Modular Medical to rapidly capture share in the multi-billion dollar “almost-pumpers” market, an enormous and still-underpenetrated segment with significant upside for disruptive entrants.

David Bosshard, Modular Medical Head Of International Operations

Momentum from Strategic Execution

This new appointment aligns perfectly with Modular Medical’s accelerating regulatory momentum. The company’s Pivot patch pump is advancing toward both FDA and European CE Mark approvals, leveraging IRB-approved feasibility studies and real-world data to ensure a fast, consumer-centric rollout. Success would position Modular not only as an innovator but potentially as a category leader for affordable, easy-to-use insulin delivery—seeking to turn millions of injection users into pump adopters globally.

Big Opportunity in the Diabetes Market

Modular Medical’s strategy aims to democratize insulin pump access, targeting mainstream diabetes populations rather than just “super users.” By offering simplicity, low cost, and minimal training, the company is well-placed to open mass-market adoption, a move that could catalyze exponential growth. Industry analysts forecast that the global insulin pump market will exceed $7 billion by 2030, and Modular’s focus on affordability and user experience places it at the heart of this expansion wave.

Analyst and Investor Optimism

Despite a volatile year for MODD shares, long-term forecasts potentialy carry a distinctly bullish tone. Analysts predict substantial upside, with price targets ranging from $3.45 in 2025 to over $10 by 2050—a potential increase of more than 1,400% from current levels. Recent technical indicators point to heightened buying interest, with increased trading volume and positive short-term signals as the stock consolidates above key support levels. Modular Medical has also enjoyed growing analyst attention and buy recommendations, as analysts anticipate a breakthrough in pump adoption and international expansion.

Leadership Stands Ready for Growth

CEO Jeb Besser and the executive team highlight Bosshard’s role as a game-changer, emphasizing confidence that seasoned leadership and an international strategy will accelerate Modular’s growth trajectory and unlock new revenue channels. With regulatory momentum on the horizon and an aggressive market entry plan, Modular Medical is believed to be well positioned to deliver shareholder value and redefine diabetes management for millions worldwide.

The Sum..

Modular Medical’s (NASDAQ: MODD) outlook is rooted in strong execution, global opportunity, and powerful leadership—all converging at a pivotal moment for the diabetes technology sector.